This multicentre, prospective study evaluated the efficacy and safety of 7-day oral moxifloxacin (400 mg/day) for treatment of acute maxillary sinusitis after first-line treatment failure (group 1), and acute sinusitis with high risk of complications (group 2). Two hundred and fifty-eight patients with radiologically confirmed acute sinusitis were enrolled by 52 investigators; 216 patients (83.7%) qualified for per protocol efficacy analysis (group 1, n = 175; group 2, n = 41), and 92 for bacteriological analysis. Samples were collected from the middle meatus. The clinical success rate 7-10 days post-treatment was 92.6%. Bacteriological success rates were 95.7% after 3-4 days of treatment, and 97.2% and 95.2%, in group 1 and group 2, respectively, at 7-10 days post-treatment. Drug-related adverse events, including abdominal pain (2.4%), nausea (2.4%) and diarrhoea (1.2%), were reported in 12.2% of patients. Overall, moxifloxacin therapy resulted in rapid bacteriological eradication, with a high rate of clinical success.
GehannoP, Berche P, the Sinusitis Study Group: Sparfloxacin versus cefuroxime axetil in the treatment of acute purulent sinusitis. J Antimicrob Chemother1996; 37 (Suppl A): 105–114.
4.
HenryDCSydnorASettipaneGAAllenJABurroughsSCobbMM: Comparison of cefuroxime axetil and amoxicillin/clavulanate in the treatment of acute bacterial sinusitis. Clin Ther1999; 21: 1158–1170.
5.
GrollierGLe MoalGRobertRBernardCKlossekJM: Rôle des bactéries anaérobies strictes dans les sinusites. Méd Mal Infect2000; 30 (Suppl 2): 109–113.
6.
NordCE: The role of anaerobic bacteria in recurrent episodes of sinusitis and tonsillitis. Clin Infect Dis1995; 20: 1512–1524.
7.
DabernatHDelmasC: Activité du Centre National de Référence des Haemophilus influenzae, années 1996-1997 le déclin du type b. Méd Mal Infect1998; 28: 940–946.
8.
BandakSITurnakMRAllenBSBolzonLDPrestonDABouchillonSK: Antibiotic susceptibilities among recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis from fifteen countries. Eur J Clin Microbiol Infect Dis2001; 20: 55–60.
9.
PeanYGoldsteinFW, Guerrier ML, le Groupe de Travail Francais: Activité des antibiotiques sur Streptococcus pneumoniae, Haemophilus influenzae and Branhamella catarrhalis isolés infections respiratoires et ORL en France: résultats une enquête multicentrique. Méd Mal Infect1998; 28: 253–257.
10.
GeslinPFremauxASissiaG: Evolution of résistance des pneumocoques responsables des infections des voies respiratoires en France. Méd Mal Infect1992; 22: 74–86.
11.
SahmDFKarlowskiJAKellyLJCritchleyLAJonesMEThornsberryC: Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2 years longitudinal analysis. Antimicrob Agents Chemother2001; 45: 1037–1042.
12.
BaqueroFGarcia-RodriguezJAde LomasJ GarciaAguilarL: Antimicrobial resistance of 1,113 Streptococcus pneumoniae isolates from patients with respiratory tract infections in Spain: results of a 1-year (1996-1997) multicenter surveillance study. The Spanish Surveillance Group for Respiratory Pathogens. Antimicrob Agents Chemother1999; 43: 357–359.
13.
Agence française de sécurité sanitaire des produits de santé: Antibiothérapie par voie générale en pratique courante. Sinusites aiguës de l'adulte, recommandations et argumentaires. Méd Mal Infect2001; 31 (Suppl 4): 493s–507s.
14.
SiegertRGehannoPNikolaidisPBagger-SjobackDIbanezJMHampelB: A comparison of the safety and efficacy of moxifloxacin and cefuroxime axetil in the treatment of acute bacterial sinusitis in adults. Respir Med2000; 94: 337–344.
15.
BurkeTVillanuevaCMarianoHJrHuckWOrchardDHaverstockD: Comparison of moxifloxacin and cefuroxime axetil in the treatment of acute maxillary sinusitis. Sinusitis Infection Study Group. Clin Ther1999; 21: 1664–1677.
16.
AdelgassJDeAbateCAMcElvainePFowlerCLLoCoccoJCampbellT: Comparison of the effectiveness of levofloxacin and amoxicillin-clavulanate for the treatment of acute sinusitis in adults. Otolaryngol Head Neck Surg1999; 120: 320–327.
17.
FishDNNorthDS: Gatifloxacin and advanced 8-methoxy fluoroquinolone. Pharmacotherapy2001; 21: 35–59.
AxelssonAChidekelN: Symptomatology and bacteriology correlated to radiological findings in acute maxillary sinusitis. J Otolaryngol1972; 74: 118–122.
20.
GehannoPBarryBChauvinJPHazebroucqJ: Clarithromycin versus amoxicillin-clavulanic acid in the treatment of acute maxillary sinusitis in adults. Pathol Biol (Paris)1996; 44: 293–297.
21.
CliffordKHuckWShanMTosielloREcholsRMHeydA: Double-blind comparative trial of ciprofloxacin versus clarithromycin in the treatment of acute bacterial sinusitis. Sinusitis Infection Study Group. Ann Otol Rhinol Laryngol1999; 108: 360–367.
22.
GwaltneyJMJrScheldWMSandeMASydnorA: The microbial etiology and antimicrobial therapy of adults with acute community-acquired sinusitis: a fifteen-year experience at the University of Virginia and review of other selected studies. J Allergy Clin Immunol1992; 90: 457–461, discussion 462.
23.
GehannoPDarantièreSDubreuilCChobautJCBobinSPagesJC: A prospective multicentre study of moxifloxacin concentrations in the sinus mucosal tissue of patients undergoing elective surgery of the sinus. J Antimicrob Chemother2002; 49: 821–826.
24.
PaavolainenMKohonenAPalvaTRenkonenAV: Penetration of erythromycin stearate into maxillary sinus mucosa and secretion in chronic maxillary sinusitis. Acta Otolaryngol (Stockholm)1997; 84: 292–295.
25.
WiseR: A review of the clinical pharmacology of moxifloxacin, a new 8-methoxiquinolone and its potential relation to therapeutic efficacy. Clin Drug Invest1999; 17: 365–387.
26.
LodeHKubinRReiterC: Safety update of oral moxifloxacin: A review of worldwide postmarketing surveillance (Abstract). 12th ECCMID. April 24-27, Milan, 2002, Abstract No. P1380.
27.
GehannoPBerchePPerrinA: Efficacité et tolérance de la moxifloxacine dans le traitement des sinusitis maxillaries aiguës en situation d'échec et des sinusitis à haut risqué de complications. Méd Mal Infect2002; 32: 494–507.
